1-866-598-7166

Latest News

NEWFOUNDLAND MEETING 2019

The Kidney Cancer Canada team hosts a Patient, Caregiver, Family and Survivor Meeting in St. John's, Newfoundland. This interactive forum features the latest information on kidney cancer treatment and what survivors should know about follow-up care. The session also gives patients, caregivers, family members and survivors a...

Thousands of Canadians begin to follow Olympic Gold Medalist in the MOVE to Beat Cancer

[vc_row][vc_column][vc_video link="https://www.youtube.com/watch?v=Vkroh1znnK4" align="center"][vc_column_text]Toronto, Ontario, Tuesday August 7, 2019 –Olympic Gold Medalist, Adam Kreek is on the MOVE to Beat Cancer to inspire others to get their MOVE on and support patient programs and research. Canadians can begin today to sign up at movetobeatcancer.org and pledge to join Adam in their self-designed MOVE and complete...

GU-ASCO 2019 Highlights

Source: International Kidney Cancer Coalition Note: The following summary was prepared by patient advocates for the benefit of patient organisations who focus on kidney cancer. While this summary has been medically reviewed, the information contained herein is based upon public data shared at this meeting and...

Cabozantinib Quebec Reimbursement Update

Please note: this statement follows our mandate to provide you information on all access issues. Kidney Cancer Canada – Cancer du rein Canada wishes to inform our community about recent developments in Quebec with regards to cabozantinib, a new treatment for patients with advanced renal...

Two kidney cancer research awards for 2019

Kidney Cancer Canada | Cancer du rein Canada in collaboration with the Kidney Cancer Research Network of Canada (KCRNC) and the Canadian Urology Association Scholarship Foundation (CUASF) fund two $50,000 research awards for kidney cancer. These awards are possible thanks to the outstanding support...

Health Canada Approves cabozantinib Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma

SOURCE : Canadian News Wire Release MISSISSAUGA, ON, Sept. 19, 2018 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the Health Canada approval of CABOMETYX™ (cabozantinib), a once-daily oral tablet,2 indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have...

Upcoming Patient Education Meetings

LIVE WEBINARUP-TO-THE MINUTE KIDNEY CANCER TREATMENT NEWSSeptember 27, 2017 | 8 pm EDT Dr Christian Kollmannsberger (BC) and Dr Anil Kapoor (ON) bring you the latest treatment information from the European Society Medical Oncology (ESMO) Annual Congress in our National Webinar. Kidney cancer survivor,...

A touching share from the Maritimes

We have come a long way in the treatment of kidney cancer since my husband was diagnosed in 2000. At the time, his prognosis was poor. There was only one treatment available in Canada and the patient response to the drug was very low. David’s...

Cabozantinib pCODR Review – Your Input is needed!

Kidney Cancer Canada is seeking input from kidney cancer patients and their caregivers about their experiences and challenges with kidney cancer and current treatments. The results of this survey will help inform our submission to the pan-Canadian Oncology Drug Review (pCODR) for the drug...

Are you helping kidney cancer research?

BY DR. NAVEEN BASAPPA and RANJENA MALONI In April 2017, the pan-Canadian Oncology Drug Review (pCODR) called for submissions on whether Axitinib should be used and funded as an equally accessible second-line treatment for metastatic kidney cancer. pCODR asked Kidney Cancer...

Shocking growth in kidney cancer rates

8 year statistics predict more than 20 percent increase TORONTO, June 20, 2017– More than 6,000 Canadians will be diagnosed with kidney cancer this year. Experts predict from 2012 to 2020, kidney cancer will increase globally by a shocking 22 percent “Populations are...

Kidney cancer expert shares hopeful new research

Kidney cancer expert shares hopeful new researchby tbnewswatch.com Thunder Bay – Thursday November 19, 2015) – Dr. Anil Kapoor was the keynote speaker at a kidney cancer treatment and emerging therapies public information session on Thursday evening at Thunder Bay Regional Health Sciences Centre...

There is Hope for Kidney Cancer Patients

There is Hope for Kidney Cancer Patientsby Sarah Chow THUNDER BAY – HEALTH – Kidney cancer is not as common as breast or prostate cancer. We don’t often hear about it in the media, or think about it when we consider our health risks....

Rises in incidence of kidney cancer

Cancer Care Ontario has release a fact sheet detailing the rising incidence of kidney cancer in Ontario and around the world. The attached sheet reports rising incidence rates in women along with contributing factors. Download Information...

Rises in incidence of kidney cancer

Cancer Care Ontario has release a fact sheet detailing the rising incidence of kidney cancer in Ontario and around the world. The attached sheet reports rising incidence rates in women along with contributing factors. Download ...

ABT-869 Trial for Advanced RCC

An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib. This trial is an Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in...

Avastin approved in EU for rcc

Avastin (bevacizumab) has been approved in Europe for first-line treatment of renal cell carcinoma.As of November 2007, Avastin has not been approved for rcc in either the U.S. or Canada. Avastin is approved in Canada for colorectal cancer, but is not funded in every province....

Axitinib showing promise for rcc

A new drug from Pfizer has demonstrated positive results in Phase II trials in the U.S.Phase III trials are open in the U.S. and some sites in Canada. Axinitib is being studied as a 2nd line treatment for mrcc (clear cell) versus sorafenib (Nexavar) For...